portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 As Vital Generic-Drug Prices Soar, So Do Pharmaceuticals’ Profits
 
CreateTime:2014-07-15     Source:Time Editor:liaoyan
Text Size:       
 

Patients are facing a sudden increase in costs for generic drugs, which is putting their health at risk, according to a report by the New York Times.

Prices for digoxin, a drug used primarily by older patients to treat rapid heart rhythm problems and heart failure, have spiked sharply in recent months.

Surveyed pharmacies had often tripled the drug’s costs from last October to June, said Doug Hirsch, chief executive of GoodRx.com, to the Times. He added that some patients reported seeing costs of more than $1,000, which can lead to hundreds of dollars in co-pay.

Alternatives to digoxin, and so market competition, are scarce. In 2013, only two businesses — Lannett Company and Global Pharmaceuticals — dominated the market after several companies stopped manufacturing the drug. Prices that year soared after one company increased its fees and the others followed suit, said the report.

Following the Times’ request for comment, Lannett wrote in an email statement, “On occasion and for a variety of reasons generic drug makers can and do raise prices.”

Whatever these reasons, they result in sudden profits. Investors told the Times that sales of Lannett’s cardiovascular drugs rose from $4.5 million to $16.9 million within just a few months.

Digoxin isn’t the only drug to be hit by price hikes. EvaluatePharma found that the cost of fiorinal with codeine, synthroid as well as the generic steroid prednisolone have doubled since 2013. In January, the National Community Pharmacists Association called for a congressional hearing to address the spiraling cost of essential generic drugs, which have risen “600%, 1,000% or more” in the past few years.

“The skyrocketing cost of scores of generic drugs is harming patients and community pharmacies and raises significant questions that deserve to be examined in a congressional committee hearing,” the association said in a statement.


Related Reports
China Contract Research Organization (CRO) Industry Report, 20...
China Human Vaccine Industry Report, 2020-2026
China Pharmaceutical Distribution Industry Report, 2019-2026
China Pharmaceutical Distribution Industry Report, 2019-2025
China Pharmaceutical Packaging Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1